Daily Tech: Tech & Health Innovation: Strong Q1 Results Signal Momentum

FutureGate | May 06 2025

Hyperscale Data ($GPUS): Solid Q1 Revenue, Confident FY Guidance Signals AI Tailwinds

Hyperscale Data, operating at the intersection of AI and infrastructure, reported preliminary Q1 revenue of $25 million — a strong early indicator for FY2025, where management reiterated full-year guidance of $115–$125 million. The company, which provides high-performance GPU-based infrastructure solutions, continues to benefit from the surge in generative AI applications, cloud computing demand, and enterprise digital transformation.

Notably, the $GPUS platform enables training and deployment of large-scale AI models across hyperscale environments. As GPU demand continues to exceed supply in many regions, Hyperscale’s revenue trajectory reflects early adoption from Tier 1 clients, potentially validating product scalability and technical reliability. The company remains one to watch, especially as capex allocations among cloud providers remain elevated and enterprise AI initiatives move from pilot to production.

Hims & Hers Health ($HIMS): Triple-Digit Revenue Growth Driven by Telehealth Demand

Hims & Hers posted a blowout Q1, with revenue up 111% YoY and subscription growth of 38%, solidifying its position as a category leader in direct-to-consumer digital healthcare. The growth was largely driven by strong traction in its weight loss offerings — where GLP-1 therapy demand has surged — alongside stable performance in mental health and dermatology.

This marks the third consecutive quarter of accelerating revenue growth, supported by recurring subscription revenue, improving unit economics, and a loyal user base. With over-the-counter treatment options expanding and prescription demand holding steady, HIMS is approaching scale and operating leverage. The business model is built on predictable cash flows, and the continued expansion into branded pharmaceutical categories positions the company for long-term defensibility. For investors, this is a case study in healthtech execution and product-market fit.

WeRide and Uber Expand Strategic Partnership to 15 Cities Globally

Autonomous mobility firm WeRide surged 21% in after-hours trading following the announcement of a major expansion with Uber. The two companies, initially piloting their partnership in Abu Dhabi and Dubai, will now scale operations across 15 new cities over the next five years. The agreement signals Uber’s ongoing commitment to automation and future-proofing its ride-hailing ecosystem.

For WeRide, this is a validation milestone. It allows the company to piggyback on Uber’s global logistics and demand infrastructure — accelerating deployment and reducing go-to-market friction. With governments increasingly supporting AV testing and urban planning initiatives leaning toward smart cities, this move places both firms at the forefront of transportation’s next paradigm shift. Investors should pay attention to operating metrics as deployments scale and regulatory environments evolve.

Element Science Receives FDA Clearance for Life-

Saving Wearable Defibrillator Patch

In a breakthrough for digital health and cardiac care, Element Science has received FDA approval for its wearable defibrillator patch — a discreet, non-invasive device aimed at reducing sudden cardiac death post-discharge. The technology provides real-time monitoring and therapeutic intervention, addressing a critical gap in the cardiac care continuum.

This is not just a product milestone but a potential shift in how post-acute care is delivered. The market for wearable medical devices is expected to grow at a double-digit CAGR over the next decade, and Element Science now finds itself at the forefront of this emerging category. With major players in medtech (e.g., Medtronic, Abbott) seeking to expand their connected care offerings, this clearance could make Element an attractive acquisition target or partner.